Table 1: Clinical data for 218 patients

From: IGF-IR: a new prognostic biomarker for human glioblastoma

Age (years)
Median (range)64 (21–81)
Gender
Female/male97/121
Multifocality
No162
Yes45
Missing11
Date of surgery
Median (range)1999 (1988–2006)
Surgical resection
Complete63
Partial140
Missing15
Adjuvant therapy
No4
Radiotherapya142
 Standard protocol (dose (Gy)/number of fractions) (median (range)): 60 (55–66)/30 (28–40)81
 Incomplete protocolb (dose (Gy)/number of fractions) (median (range)): 32 (20–54)/10.5 (10–27)17
 Missing44
Radiotherapy+temozolomidea26
 Radiotherapy 
  Standard protocol (dose (Gy)/number of fractions) (median (range)): 60 (54–64)/30 (20–33)21
  Incomplete protocolb (dose (Gy)/number of fractions) (median (range)): 39.5 (39–40)/16.5 (13–20)2
  Missing3
 Temozolomide 
  Concomitant (=every day during radiotherapy) 
   Dose (mg m2 day−1): 7512
   Missing14
  Adjuvant 
   Dose (mg m2 day−1)/number of cycle (median (range)): 187.5 (100–200)/3 (1–9)15
   Missing11
Othersc11
Missing35
Follow-up (months)
Median (range)8 (0–90)
Death77.1%
Median survival (months)10
  1. The table displays the numbers (or percentage) of cases except when other features are indicated (such as median and range).
  2. aConsidered as standard therapies.
  3. bFor reasons such as clinical degradation of patients.
  4. cIncluding non-standard therapies for GBM patients, such as chemotherapy alone or combined with radiotherapy or palliative management.